Perspective Therapeutics, Inc. (CATX)

1,6950 +0,0150 (+0,89%) A partir del 11:05AM EDT. Mercado abierto.

Perspective Therapeutics, Inc.

2401 Elliott Avenue
Suite 320
Seattle, WA 98121
United States
206-676-0900
https://www.perspectivetherapeutics.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 116

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Johan M. Spoor	CEO & Director	855,78k	N/A	1972
Mr. Jonathan R. Hunt	CFO & Co-Principal Financial Officer	944,35k	N/A	1967
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer	633,14k	N/A	1966
Mr. Shane Cobb	Executive Vice President of Operations	N/A	N/A	N/A
Mr. Mark J. Austin CPA	VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary	N/A	N/A	1987
Dr. Michael K. Schultz Ph.D.	Chief Science Officer	N/A	N/A	N/A
Mr. Andrew Bright	Executive Vice President of Brachytherapy	N/A	N/A	N/A
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer	N/A	N/A	N/A
Dr. Frances L. Johnson M.D.	Chief Innovation Officer	N/A	N/A	N/A
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Gobierno corporativo

El ISS Governance QualityScore de Perspective Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.